LG Chem has granted global licensing rights for an oral treatment for rare obesity disorders to U.S.-based Rhythm Pharmaceuticals Inc., which is now set to begin its active development. On the 24th, Rhythm Pharmaceuticals, LG Chem’s partner, announced the initiation of the first patient dosing in a Phase 2 clinical trial for LB54640. See more: https://lnkd.in/gCrNVBQF #LGChem #WeConnectScience #LifeSciences
LG Chem’s Post
More Relevant Posts
-
In a manuscript published in the Journal of Pharmacy & Pharmaceutical Sciences, Lumanity’s Steven Weisman and Giovanni Ciavarra, along with co-author Grant Cooper (Princeton Spine and Joint Center) have explored the current treatments used for non-specific low back pain (LBP), with a focus on naproxen sodium. Read more here: https://buff.ly/49kHv0m #ClinicalandRegulatory #LowBackPain #Journalarticle #Newpublication #NSAIDs
-
In a manuscript published in the Journal of Pharmacy & Pharmaceutical Sciences, Lumanity’s Steven Weisman and Giovanni Ciavarra, along with co-author Grant Cooper (Princeton Spine and Joint Center) have explored the current treatments used for non-specific low back pain (LBP), with a focus on naproxen sodium. Read more here: https://buff.ly/3UvOqzH #ClinicalandRegulatory #LowBackPain #Journalarticle #Newpublication #NSAIDs
What a Pain in the … Back: A Review of Current Treatment Options with a Focus on Naproxen Sodium
-
New progress from Gan & Lee Pharmaceuticals & Lee - their glucagon-like peptide-1 receptor agonist GZR18 has reached the primary endpoint and all critical secondary endpoints in the Phase Ib/IIa clinical study. The complete data from the trial is set to be unveiled at this year's ADA and EASD annual meetings. #QMportfolio #QMhealthcare #ClinicalTrials #MedicalResearch #DiabetesCare #GanAndLee
-
-
...proud, as this research started more than 10 years ago at KU Leuven when we were looking for compounds that can increase the activity of antifungal drugs. In this way, we identified the very potent and fungicidal miconazole - domiphen bromide combination, which now proved to be more effective in patients than standard-of-care. …with support of Industrial Research Fund (IOF) and VLAIO #translationalresearch
Hyloris Pharmaceuticals and Purna Female Healthcare announce positive results from phase 2 trial in patients with acute vulvovaginal candidiasis (VVC). The next steps are to engage in discussions with relevant authorities for further clinical investigations. https://lnkd.in/e5YvyEgb
-
Today, Idorsia Pharmaceuticals Ltd announced the FDA approval of TRYVIO (aprocitentan), marking it the first and only endothelin receptor antagonist for the treatment of hypertension in combination with other antihypertensive drugs to reduce blood pressure in adult patients who are inadequately controlled on other therapies. This approval is based on the Phase 3 multicenter study evaluating the efficacy of TRYVIO in adults with systolic blood pressure (SBP) ≥140 mmHg who were on at least three antihypertensive medications. The study showed that TRYVIO 12.5 mg significantly reduced SBP compared to placebo at Week 4, and its blood pressure-lowering effect persisted throughout the trial. Read More: https://lnkd.in/eWAEHrTr #FDAApproval #Hypertension #Idorsia #TRYVIO
-
-
Founder of Law Offices of Scott Glovsky | Skilled trial attorney | Insurance Bad Faith, Catastrophic Personal Injury, Sexual Abuse, Healthcare Litigation
The Journal of Managed Care & Specialty Pharmacy published an article predicting some of the next pharmaceutical #medications to appear on Medicare's drug negotiation list. They include medications for cancer, diabetes, GI disorders, and more. Read below. #Medicare #healthinsurance
-
-
Idiopathic Pulmonary Fibrosis Pipeline Assessment | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, & Clinical Trials | Aria Pharmaceuticals, InSilico Medicine, AdAlta #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech
Idiopathic Pulmonary Fibrosis Pipeline Assessment | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, & Clinical Trials | Aria Pharmaceuticals, InSilico Medicine, AdAlta | ABNewswire
-
Biologist|| Passionate Content Creator & Story Teller || Techno Commercial Professional in Oncology Biosimilars/GLP 1 Biologics/Pre Clinical/BABE studies /Patient based Clinical Trial across Phases
Sun Pharma and Moebius Medical gain fast track designation for MM-II for the treatment of Osteoarthritis Knee Pain. Sun Pharmaceutical Industries (and its subsidiaries or associate companies) and Israel-based Moebius Medical announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the treatment of osteoarthritis knee pain. Planning for confirmatory Phase 3 clinical trials for MM- II is underway. MM-II is a novel non-opioid product that uses a proprietary suspension of large, empty, multilamellar liposomes which are intended to reduce friction and wear on the joint and thus relieve joint pain.
-
-
We're thrilled to invite you to our upcoming webinar: 'Benefits of Silicone-oil-free Syringe Systems.’ Our webinar will offer an in-depth look at how we have meticulously designed our prefilled syringe portfolio for ophthalmology to align with the rigorous standards of this specialized therapeutic field. In line with our commitment to excellence and the evolving landscape of drug technologies, we are proud to unveil our comprehensive prefilled silicone-oil-free syringe systems. Collaborating closely with our pharmaceutical partners, we're dedicated to advancing patient care and well-being. We have eliminated free silicone oil from the components of our prefilled syringe systems. This proactive measure not only mitigates the risk of drug interaction during storage but also minimizes potential post-injection risks to patients, ensuring unrivaled functionality in the market. Learn more about our speakers: Bernd Zeiß Zeiss and Maximilian Vogl Registration: https://lnkd.in/e6An8DF7 #innovatingforabetterlife #webinar #syringes #pharma #biotech #drugdelivery
-
